Teacher Retirement System of Texas Has $1.31 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Teacher Retirement System of Texas lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 18.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,565 shares of the biopharmaceutical company’s stock after acquiring an additional 6,742 shares during the quarter. Teacher Retirement System of Texas’ holdings in TG Therapeutics were worth $1,311,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of TGTX. State Street Corp boosted its stake in TG Therapeutics by 35.8% in the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in TG Therapeutics by 7.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock worth $38,212,000 after buying an additional 84,904 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in TG Therapeutics by 10.5% during the 4th quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company’s stock worth $27,797,000 after acquiring an additional 87,679 shares during the last quarter. Principal Financial Group Inc. increased its position in TG Therapeutics by 7.5% in the 4th quarter. Principal Financial Group Inc. now owns 830,184 shares of the biopharmaceutical company’s stock valued at $24,989,000 after acquiring an additional 57,996 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of TG Therapeutics by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock worth $16,859,000 after acquiring an additional 270,286 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 11,337 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.50% of the company’s stock.

TG Therapeutics Trading Down 0.8 %

NASDAQ:TGTX opened at $39.86 on Friday. TG Therapeutics, Inc. has a 1-year low of $12.93 and a 1-year high of $43.32. The business’s 50-day moving average price is $34.37 and its two-hundred day moving average price is $30.29. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $6.26 billion, a price-to-earnings ratio of -398.56 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. On average, equities analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

TGTX has been the topic of several research reports. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.